ArcheMedX, a behavioral science-based learning company providing a smarter way to predict and improve clinical team performance, recently passed a significant data milestone.
PRWeb - Charlottesville, VA March 24, 2022
Today, the Company announced its clinician learning and predictive analytics platform, Ready, has now surpassed more than 25 million essential learning behaviors
The area of clinical research known as CNS (central nervous system conditions) is commonly cited for its complexity and the subjective nature of many assessment tools. CNS clinicians therefore must commit to tackling unique challenges affecting their patients and the research they conduct.
It should be no surprise that the life
Today, ArcheMedX announced that its 2020 industry report, “COVID-19's Impact on Virtual Tech in Clinical Trials, was honored with a prestigious American Marketing Association (AMA) award.
Every year, the AMA honors hundreds of stand-out marketers through awards programs presented by the AMA Foundation, local professional chapters, and academic special interest groups.
Watch on Demand Now!
Clinical trials are more complex than ever.
And 85% of them are delayed.
More screening criteria, more procedures, new vendor systems and tools, and more data. So who bears the burden of all this progress? Sites.
Increased site burden means degraded performance, more delays, and more problems for you. But
CHARLOTTESVILLE, VA Apr. 21, 2021 -- ArcheMedX announced today that ValenzaBio, a biotech focused on developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, has selected Ready, the industry’s leading clinical trial learning and predictive analytics platform, to optimize performance on its upcoming Phase II study.
ValenzaBio is deploying Ready to